Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 08:04   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

2390  4949  532  300 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 206.68+1.10 
 EEM 42.44+1.31 
 PBR 10.84+1.13 
 EWZ 43.95+2.82 
 BAC 17.12+0.12 
 KMI 39.75-0.17 
 AAPL 116.47+0.16 
 INTC 35.59-0.36 
 VALE 9.41+0.72 
 GDX 19.88+0.17 
Partners & Brokers